Novo to open development ops in Seattle

Novo Nordisk's push to explore new therapeutic areas has brought it to Seattle, WA, where the Danish company plans to open a research center. The developer, which is known for its diabetes drugs, is pursuing development of oncology and inflammation drugs, and Seattle seems like just the place to do that. "There is a pool of talent in Seattle and a track record of therapeutic discovery here," Don Foster, who will head the site, told the Seattle Post-Intelligencer. "I think the idea is that Seattle has got some infrastructure. It is a nucleus for research in this area." Amgen and ZemoGenetics, which are both pursuing similar indications, are also based in the region.

Novo Nordisk will focus on several diseases, including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythmatosus. This site is expected to open in 2010 and will employ 80 people.

- read this Seattle Post-Intelligencer article for more

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.